Today both U S News and Reuters are reporting that Johnson and Johnson (NYSE: JNJ) are considering selling LifeScan for $3.4 billion. According to these reports;
“Among the potential bidders is a consortium being formed by Shenzhen-listed Sinocare Inc, which develops and manufactures blood sugar monitoring systems, and China Jianyin Investment Ltd (JIC), a unit of sovereign wealth fund China Investment Corp. The group has hired an advisor to work on a bid, according to two sources.”
This really isn’t news to Diabetic Investor as we have chronicled this process since JNJ announced they were considering all . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.